financetom
Business
financetom
/
Business
/
Update: Ecora Resources Loses 3% As Provides Portfolio Update
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Ecora Resources Loses 3% As Provides Portfolio Update
Mar 6, 2024 9:11 AM

11:40 AM EST, 03/06/2024 (MT Newswires) -- Ecora Resources PLC ( ECRAF ) , a royalty company, earlier on Wednesday issued a portfolio update after operators of key projects in Ecora's loyalty and stream portfolio provided public market updates.

The company continues to expect volume growth in 2024 at operations underlying its producing royalty portfolio. At current commodity price levels, that would imply year-on-year portfolio contribution growth.

Adaro/EMR Capital's Kestrel mine is forecast to produce 1.8-2.0 mt of steelmaking coal in 2024, up from 1.6 mt produced in 2023.

Capstone Copper Corp. (CS.TO)'s Mantos Blancos mine is expected to produce 49-57 kt of copper in 2024, compared with 49.5 kt produced in 2023.

Vale SA's Voisey's Bay mine is forecast to produce 240-320 t of copper in 2024, up from 220 t produced in 2023.

Largo Resources Inc. (LGO.TO)'s Maracas Menchen mine is expected to produce 8.7-10.7 kt of vanadium in 2024, compared with 9.4 kt produced in 2023.

Cameco Corp. (CCO.TO)'s Cigar Lake mine is forecast to produce 18 Mlbs of uranium in 2024, up from 15.1 Mlbs produced in 2023.

Quasar Resources' Four Mile mine is forecast to produce 4.5-5.0 Mlbs of uranium in 2024, compared with 5.0 Mlbs produced in 2023.

Ecora at last look fell 3.0% in early Wednesday trading.

Price: 1.31, Change: -0.04, Percent Change: -2.96

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Oct 10, 2024
09:25 AM EDT, 10/10/2024 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Thursday that volixibat has received breakthrough therapy designation from the US Food and Drug Administration as a potential treatment for cholestatic pruritus related to primary biliary cholangitis. The company said the designation is based on the interim analysis of a phase 2b study that demonstrated statistically significant...
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Oct 10, 2024
09:24 AM EDT, 10/10/2024 (MT Newswires) -- Delta Air Lines ( DAL ) issued a weak fourth-quarter earnings outlook amid expectations for subdued travel demand around the US Presidential elections in November, as the air carrier's bottom line fell short of market estimates in the prior three-month period while revenue beat Wall Street forecasts. The airline anticipates adjusted earnings to...
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Oct 10, 2024
Indivior PLC ( INDV ) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects third-quarter net revenue of $302 million – $309 million versus the consensus of $289.37 million. Also, Indivior ( INDV ) trimmed its FY24 net revenue outlook to $1.125 billion – $1.165 billion (consensus $1.185 billion) from $1.15 billion –...
Starboard seeks probe after former Pfizer execs pull support for its campaign
Starboard seeks probe after former Pfizer execs pull support for its campaign
Oct 10, 2024
(Reuters) - Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior executives were forced to publicly declare support for CEO Albert Bourla, the hedge fund said on Thursday. Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, who were reportedly helping the activist investor in its plan to push...
Copyright 2023-2026 - www.financetom.com All Rights Reserved